Equity Overview
Price & Market Data
Price: $1.10
Daily Change: +$0.035 / 3.20%
Daily Range: $1.04 - $1.10
Market Cap: $20,223,356
Daily Volume: 118,314
Performance Metrics
1 Week: -8.75%
1 Month: 11.85%
3 Months: -7.20%
6 Months: 28.33%
1 Year: -61.71%
YTD: -72.62%
Company Details
Employees: 23
Sector: Health technology
Industry: Medical specialties
Country:
Details
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.